Skip to main content

This website contains promotional content and is intended for Healthcare Professionals

Key Takeaway

In clinical practice, PCSK9i (alirocumab or evolocumab) on top of maximum LLT significantly reduced LDL-C levels (by 58%) and improved LDL-C target achievement in patients with heterozygous FH (both in men and women).

LDL-C goals*:

  •  2016 ESC/EAS goals†: Patients with ASCVD = 67%; patients without ASCVD = 80%
  •  2019 ESC/EAS LDL-C goals‡: VHR patients = 46%; HR patients = 50%

Independent predictors for LDL-C goals: Male gender; smoking; and use of statins + ezetimibe

Why This Matters

  • § Use of PCSK9i in clinical practice is less frequent (partly due to cost and insurance issues).
  • Safeheart registry study assessed the use and efficacy of PCSK9i as well as LDL-C goals attainment in clinical practice setting of FH patients.

Study Design

Safeheart: Open, Multicenter, Nationwide, Long-term Prospective Study (N = 433 [Alirocumab = 211; Evolocumab = 222])

Key Inclusion Criteria

Patients with molecular diagnosis of FH (aged ≥20 years) on stable LLT, who received PCSK9i (alirocumab 75/150 mg every 2 or 4 weeks, or evolocumab 140 mg every 2 weeks or 420 mg every 4 weeks) from 2016 to January 2020

Key Exclusion Criteria

Patients who participated in RCTs with PCSK9i before 2016

LDL-C Goals: Defined and analyzed based on 2016 and 2019 ESC/EAS guidelines

Key Results

Overall, 433 patients were included in the analysis

Mean age = 55 years; male = 53%; history of ASCVD = 39%; median follow-up = 2.5 years

LDL-C Levels:

  • Before PCSK9i: Median LDL-C = 145 mg/dL (IQR: 125–173)
  • After addition of PCSK9i: LDL-C levels reduced by 58% (IQR: 41–70 [P <0.001]) in men and women without differences between both PCSK9i 
    Median LDL-C = 62 mg/dL (IQR: 44–87)

LDL-C Goals*

  • 2016 ESC/EAS goals†: Patients with ASCVD = 67%; patients without ASCVD = 80%
  • 2019 ESC/EAS LDL-C goals‡: VHR patients = 46%; HR patients = 50%
  • Higher LDL-C levels before PCSK9i initiation had a significant inverse relationship with goals attainment

Independent Predictors (2019 ESC/EAS LDL-C GOALS)

  • Male gender (P = 0.023); smoking (P = 0.041); and use of statins + ezetimibe (P = 0.008)

Limitations

  • Study lacked blinding randomization
  • Follow-up analysis was not centralize
  • In the follow-up analysis, Lp(a) measurement was not available

* Without differences between alirocumab or evolocumab.
 LDL-C target below 70 mg/dL and 100 mg/dL, respectively according to 2016 ESC/EAS guidelines.
 LDL-C goal according to 2019 ESC/EAS guidelines (for VHR patients <55 mg/dL; for HR patients <70 mg/dL).
§ International guidelines recommend PCSK9i for patients with FH with substantially higher LDL-C levels despite maximally tolerated statin ± ezetimibe.
 Kept a stable dose of PCSK9i at least 3 months before the last analysis. PCSK9i eligibility was based on Spanish National Health System reimbursement regulations in FH patients.

MAT-BH-2200043/v1/Jan 2022